Xanthus Pharmaceuticals, Inc. Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals, Inc. today announced the presentation of updated results based on follow-up data as of December 2007 from the Company’s completed Phase 2 study of Xanafide® in combination with cytarabine (ara-C) in patients with secondary acute myeloid leukemia. The presentation was made by Harry P. Erba, M.D., Ph.D., Associate Professor of Internal Medicine at the University of Michigan Health System, at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). Xanafide is a DNA intercalator that induces apoptotic signaling by blocking TopoII binding to DNA, and is now in a randomized Phase 3 registration trial under a special protocol assessment (SPA) agreement with the US Food and Drug Association (FDA) for the treatment of secondary AML.